Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5702757 | Urologic Oncology: Seminars and Original Investigations | 2017 | 9 Pages |
Abstract
We estimate that in a cohort of patients who receive chemotherapy and undergo transurethral resection before cystectomy, 38% of pathologic response can be attributed to transurethral resection. Understanding who responds to chemotherapy and who responds to transurethral resection is needed to measure the effectiveness of both interventions.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Aaron B.S., Max M.D., Meera R. B.A., B.S., Hiten D. M.D., M.P.H., Nikolai A. M.D., Ph.D., George J. M.D., Alex S. M.D., Ph.D., Noah M. M.D., Phillip M. M.D., Trinity J. M.D., Ph.D.,